Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The AI-generated claim accurately reflects FDA label boxed warning content for Rexulti: increased mortality in elderly patients with dementia-related psychosis and the boxed warning titled suicidal thoughts and behaviors.
Category Scores
Accurate Statements
WARNING: Increased mortality in elderly patients with dementia-related psychosis
Supported by REXULTI boxed warning titled "Increased Mortality in Elderly Patients with Dementia-Related Psychosis" and also addressed in Warnings and Precautions section 5.1.
Suicidal thoughts and behaviors
Supported by REXULTI boxed warning titled "Suicidal Thoughts and Behaviors" (with details in Warnings and Precautions section 5.2).
Unsupported Statements
Contradictions
Important Omissions
No patient population/drug-class context for "Suicidal thoughts and behaviors" (boxed warning is specifically framed around antidepressants and pediatric/young adult populations in short-term studies).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The statements are limited to warning titles and do not add dosing, contraindications, or clinical instructions. The only limitation is lack of contextual qualifiers for the suicidal thoughts/behaviors warning.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
The suicidal thoughts and behaviors warning is reproduced without the label’s key context (antidepressant class and pediatric/young adult framing).
Suggested Improvement
Quote or paraphrase the boxed warning with its contextual framing (risk with antidepressants in pediatric/young adult patients) to match the labeling more precisely.